FSD Pharma advancing its Phase 1 study in Australia

viewFSD Pharma

Inc () (NASDAQ:HUGE) CEO Raza Bokhari sat down with Proactive’s Christine Corrado at BIO CEO in New York. Bokhari says the Cobourg, Ontario-based company will initiate Phase 1 safety trials in patients for its lead drug candidate PP 101 micro-PEA in before the end of 1Q, aiming to treat symptoms related to fibromyalgia, a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues.


Market: CSE
Market Cap: $61.19 m

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...


Deep dive

FSD Pharma facility

FSD Pharma is building a mammoth hydroponic indoor cannabis production...

Most read

FSD Pharma rings the Nasdaq opening bell in 'exciting and momentous moment'

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) CEO Raza Bokhari, who runs the pharmaceutical cannabis research company, rang the Nasdaq opening bell together with with members of the board, leadership team, early investors, and others. Bokhari says it was an 'exciting and momentous moment' for the...

2 weeks, 5 days ago

2 min read

Harvest One Cannabis embarks on review of strategi...
EuroLife Brands establishes European advisory coun...

Related Posts